MedTrace Logo

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

NCT02830932 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2018-08-16

No results posted yet for this study

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL

VXA-RSV-f Tablets (high dose)

The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.

OTHER

VXA Placebo Tablets

The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.

BIOLOGICAL

VXA-RSV-f Tablets (low dose)

The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose

Sponsors & Collaborators

  • Vaxart

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2016-09-16
Completion
2017-09-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02830932 on ClinicalTrials.gov